Back to search
FLT3 Gene Mutation
Clinical trial pipeline · Data from ClinicalTrials.gov
See which FLT3 Gene Mutation trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which FLT3 Gene Mutation trials you may qualify forThis phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in trea…
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin…
This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy t…
The study population consisted of FLT3-ITD-mutated AML patients who were FLT3-ITD-positive before allogeneic hematopoietic stem cell transplantation. This open-…
This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come b…
This phase I/II trial studies the best dose of gilteritinib given together with ASTX727 and venetoclax and the effect of ASTX727, venetoclax, and gilteritinib i…
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were ref…
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind…